After LGZGD administration, the pharmacokinetic profiles of the seven compounds were significantly altered in NAFLD rats when compared to normal rats, which might be attributed to the decreased expression of UGT1A1 metabolizing enzymes and the nine transporters in NAFLD rats. Here, UGT1A1 is linked to metabolic dysfunction-associated steatotic liver disease.